24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
Walk into any facility and sustainability stops being abstract. Cleanrooms run continuously. Cleaning cycles consume water and energy. Packaging lines generate scrap during start-up and changeovers. For many teams, pharmaceutical production sustainability starts with a practical question: what can be improved without triggering quality risk, revalidation delays, or audit findings?
Many significant changes are found within familiar engineering and quality disciplines. When viewed as performance work, sustainability provides better control, fewer deviations, and reduced costs.
Environmental expectations are tightening across markets, and manufacturers feel this in new documentation requirements and customer questionnaires. The European Medicines Agency (EMA) Environmental Risk Assessment (ERA) guideline sets out how environmental risks should be assessed and documented for human medicines; the updated revision was published in August 2024.
Inside plants, the pressure is also commercial. Utility pricing volatility has made energy and water usage visible on the balance sheet. At the same time, procurement teams are asking suppliers for clearer emissions data, including Scope 1 (direct), Scope 2 (purchased energy) and Scope 3 (value chain) impacts.
For Quality teams, the key is method. International Council for Harmonisation (ICH) Q9(R1) reinforces risk-based decision-making, with the level of formality matching the level of risk. This principle aligns well with sustainability work because it frames change control in terms of patient and product protection.
Energy reduction often starts in the cleanroom. Heating, Ventilation, and Air Conditioning (HVAC) can account for a large share of site energy. Industry reporting and peer-reviewed work cite figures of around 50% in some pharmaceutical settings.
Before choosing technical options, it helps to set expectations. The biggest wins typically come from airflow strategy, control philosophy, and equipment condition monitoring. The list below shows where teams often start.
Practical examples include transitioning from constant-volume to variable-air-volume systems where risk assessments permit, tightening differential-pressure control loops, and using calibrated particle counters and humidity sensors to prevent over-conditioning. Teams also review filter-loading trends because clogged high-efficiency particulate air (HEPA) filters increase fan power.
On the equipment side, motor and pump upgrades can reduce draw, yet the real value comes when energy data is tied to performance metrics such as Overall Equipment Effectiveness (OEE). When energy spikes correlate with micro-stoppages, maintenance teams gain a new diagnostic signal.
Water use is often underestimated until a site maps cleaning and utilities are considered. Water for Injection (WFI) generation, distribution-loop temperatures, and Cleaning-In-Place (CIP) cycles add up quickly.
Solvent-heavy processes can reduce environmental impact through tighter containment and recovery, while improving control of raw material costs. Technical teams look for sealed transfer, validated condensers, and recovery skids with traceable instrumentation calibration. A strong supplier will discuss mass balance and vent treatment, rather than staying at the brochure level.
CIP and Sterilisation-In-Place (SIP) optimisation tends to focus on cycle design, rather than aggressive chemical changes. Examples of adjustments professionals will recognise include adjusting pre-rinse conductivity endpoints, validating lower rinse volumes with swab data, and reducing heated hold times where bioburden data support it. These changes require disciplined documentation but can reduce water and steam use and downtime.
Packaging sustainability often starts with line stability. Poor start-up control creates reject bins filled with good material that never reaches patients.
Common technical focus points include:
Serialisation adds complexity. When aggregation logic is unstable, rework increases and the risk to data integrity grows. Stability here reduces both waste and administrative load.
A large share of environmental impact sits upstream, which is why supplier qualification is changing. Procurement teams increasingly ask for emissions-reporting maturity, transport-lane logic, and change-notification discipline.
This is where sourcing conversations around active pharmaceutical ingredients and excipients move from theory to practice. Variability drives over-processing, extra testing, and scrap. Better supplier controls can reduce environmental impact indirectly by stabilising batches and reducing rework.
Sustainability work needs metrics that Quality can stand behind. A useful approach is to track two sets of measures:
Risk management guidelines in ICH Q9(R1) support this, as change impact is evaluated through hazard identification, controls, and residual risk. The World Health Organization (WHO) Good Manufacturing Practice (GMP) guidance also emphasises consistent control as a means of reducing contamination, mix-ups, and errors.
For exhibitors, pharmaceutical manufacturing trade shows are most effective when discussions are specific. Bring operating ranges, room grades, utilities constraints, and validation expectations. Share the current pain points, such as HEPA pressure drop trends, CIP cycle times, or reject drivers on a blister line. Those details accelerate technical fit checks. Submit a Pharmtech exhibit enquiry outlining the technologies and services you provide and the buyer profiles you aim to reach.
